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ABSTRACT
The development of alternative methods to animal experimentation has progressed rapidly over the last 20 years. Today, in vitro and 
in silico methods have an important role in the hazard identification and assessment of toxicology profile of compounds. Advanced 
alternative methods and their combinations are also used for safety assessment of final products. Several alternative methods, which 
were scientifically validated and accepted by competent regulatory bodies, can be used for regulatory toxicology purposes, thus 
reducing or fully replacing living animals in toxicology experimentation. The acceptance of the alternative methods as valuable tools 
of modern toxicology has been recognized by regulators, including OECD, FDA and EPA. 
This paper provides a brief overview of the topic “alternative methods in toxicology” and focuses on pre-validated and validated 
alternative methods and their position in the modern toxicology.
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These three principles, also known as the “3Rs”, 
were defined in 1959 by W.M.S. Russell and R.L. Burch 
in their well-crafted and scientifically valid writing on 
this subject, “The Principles of Humane Experimental 
Techniques” (Russell & Burch, 1959).
Reduction is defined as any decrease in the numbers 
of animals used to obtain information of a given amount 
and precision; Refinement is defined as any decrease 
in the incidence or severity of procedures applied to 
animals; and Replacement is defined as the substitution 
of conscious living vertebrates by non-sentient mate-
rial. These three types of alternative procedures are not 
mutually exclusive; for example, an in vitro test could 
serve as a partial replacement for an animal test (i.e. it 
could replace the use of the animal test for certain kinds 
of test substances, or for a particular type and/or range 
of toxicological hazard). However, if the in vitro test were 
used in the context of a tiered testing strategy, it could 
also serve as a reduction and/or refinement alternative 
(i.e. it could reduce the number of substances tested in 
Introduction
The development of alternative methods to animal 
experimentation has progressed rapidly over the last 20 
years. Knowledge of alternative methods and their use 
in planning and conducting toxicology experiments has 
become essential for modern toxicologists. 
Alternative methods (alternative toxicology tests) are 
methods able to: 
• reduce the number of animals necessary in a test, 
• refine toxicology procedures to make them less 
painful or stressful to laboratory animals, or, 
• replace animals with non-animal (in vitro, ex-vivo 
or in silico systems). 
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CAAT: Centre for Alternatives to Animal Testing; ECVAM: European Centre For Validation of Alternative Methods; EPA: Environmental Protection 
Agency; ESAC: ECVAM’s Scientific Advisory Committee; FDA: Food and Drug Administration; FRAME: Fund for the Replacement of Animals in Medical 
Experiments; GD: Guidance Document; ICCVAM: Interagency Coordinating Committee on the Validation of Alternative Methods; JaCVAM: Japanese 
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activity relationship; TG: Test Guideline; ZEBET: German National Center for Evaluation and Assessment of Alternative methods. 108
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animals, and particularly the number of toxic substances 
tested) (Russell & Burch, 1959).
The 3Rs provide a strategy for a rational and stepwise 
approach to minimising animal use and suffering in 
experiments, without compromising the quality of the 
scientific work being undertaken. A number of useful 
alternative methods have been developed for evaluation 
of the potential toxic effects of chemicals and products 
since publication of the 3Rs principles. However, it still 
takes many years to implement these principles into the 
toxicology praxis. Since 1986, the concept of the 3Rs has 
been supported by laws in the EU that require researchers 
and investigators to use available alternatives before con-
ducting in vivo experimentation. The 3Rs Declaration 
of Bologna, which was adopted in 1999 by the Third 
World Congress on Alternatives and Animal Use in 
the Life Sciences, strongly endorsed and reaffirmed the 
principle of the 3Rs. Today, Reduction, Refinement and 
Replacement are basic tenets of EU research and other 
policies concerning the use of animals in scientific testing 
and experimentation. 
The Council Directive 86/609/EEC on the protection 
of animals used for experimental and scientific purposes 
in article 7.2 states: 
“An experiment shall not be performed if another 
scientifically satisfactory method of obtaining the result 
sought, not entailing the use of an animal, is reasonably 
and practicably available“. 
Article 23 further states: 
“The Commission and Member States should encour-
age research into the development and validation of 
alternative techniques which could provide the same level 
of information as that obtained in experiments using ani-
mals, but which involve fewer animals or which entail less 
painful procedures, and shall take such other steps as they 
consider appropriate to encourage research in this field. 
The Commission and Member States shall monitor trends 
inexperimental methods”.
As a response to articles 7 and 23 of the Council 
Directive 86/609/EEC, the European Centre for the 
Validation of Alternative Methods (ECVAM) was estab-
lished in 1991. ECVAM was given the task to scientifically 
evaluate and validate alternative methods, to serve as an 
information centre, and to maintain a database on in vitro 
tests and validated methods. Once a method has under-
gone a formal validation, an independent peer-review 
process takes place. Subsequently, the ECVAM Scientific 
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Figure 1. Scheme of prospective validation study.109
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Advisory Committee (ESAC) gives advice on the scien-
tific validity of the method. ECVAM also monitors the 
research projects funded by the European Commission, 
and maintains links with relevant platforms and associa-
tions devoted to reduction, refinement, and replacement 
(3Rs of animal use for scientific and regulatory purposes. 
Recently, two additional committees, PARERE (Network 
of European Regulators) and ESTAF (Institutions with 
vested interest in development and use of alternative 
methods) have been established to help ECVAM in iden-
tification of the most promising alternative method with 
regulatory relevance. 
Why do we need to validate 
alternative methods?
The validation process ensures that alternative methods 
developed by academic or industrial scientists will be sci-
entifically valid and thus, eventually accepted by regula-
tory authorities for classification and labeling, product 
approval or safety testing purposes. Examples of where 
validated methods are required to generate toxicology 
data include e.g.: 
•  REACH (Registration, Evaluation, Authorization 
of Chemicals)
•  Cosmetic directive 76/768/EEC (VII Amendment)
•  Classification and Labelling of Chemicals and 
Transport regulations
Test  method validation is a process based on sci-
entifically sound principles by which the reliability and 
relevance of a particular test, approach, method, or pro-
cess are established for a specific purpose. Reliability is 
defined as the extent of reproducibility of results from a 
test within and among laboratories over time, when per-
formed using the same standardised protocol. Relevance 
of a test method describes the relationship between the 
test and the effect in the target species and whether 
the test method is meaningful and useful for a defined 
purpose, with the limitations identified. In brief, it is the 
extent to which the test method correctly measures or 
predicts the (biological) effect of interest, as appropriate. 
Regulatory need, usefulness and limitations of the test 
method are aspects of its relevance. New and updated 
test methods (both in vivo and in vitro) need to be both 
reliable and relevant, i.e., validated (Worth & Balls, 2004; 
Balls et al., 1990a,b).
Validation criteria for new toxicological test meth-
ods in use today were developed as collaborative efforts 
o f l ea d sci e n tists fr o m bo th th e in vivo and in vitro 
communities, regulators and other experts beginning 
in the early 1980’s. The process was carried out under 
the auspices of three organizations: the Organisation 
for Economic Cooperation and Development (OECD), 
the European Centre for the Validation of Alternative 
Methods (ECVAM), and the Interagency Coordinating 
Committee on the Validation of Alternative Methods 
(ICCVAM). These international organizations have 
worked together with external experts and national orga-
nizations such as FRAME, ZEBET and CAAT on harmo-
nizing the validation criteria so that there are no major 
differences between them amongst different countries 
and continents (Worth & Balls, 2004). Pre-validation and 
validation principles and criteria for how validation stud-
ies of new or updated test methods should be performed 
are described in detail in the OECD Guidance Document 
34 (OECD, 1990).
Typically, there are two types of validation studies, 
prospective and retrospective validation. A prospective 
study involves generation of new data while a retrospec-
tive study re-assesses existing data. A typical prospective 
validation process is composed of 6 stages (see Figure 1). 
A retrospective study is usually limited to the evaluation 
of data submitted in a standardized and recommended 
form requested by particular organization performing 
the evaluation. A test is considered validated when its 
performance characteristics, advantages, and limitations 
have been adequately determined for a specific purpose. 
The measurement of a test’s reliability and relevance and 
required for both types of validation studies.
Predictive ability and reliability of a test is judged by:
•  Sensitivity: the percentage of positive chemicals 
correctly identified. 
•  Specificity: the percentage of negative chemicals 
correctly identified.
•  Predictivity: the percentage of predictions for a 
particular classification, which were correct.
•  Accuracy: the overall percentage of correct 
classifications.
Other parameters assessed by the 
biostatistician during validation are:
•  Reproducibility within laboratories – concor-
dance of the classifications between 3 and more 
independent runs in single laboratory.
•  Reproducibility between laboratories – concor-
dance of the classifications between laboratories.
•  Probability for correct classification.
Alternative methods and models used 
for reduction & replacement
The following systems can be used as partial or full 
replacements of animals in toxicology experiments: i) in 
vitro methods (primary cultures, finite lifespan cell lines, 
continuous cell lines, reconstructed 3D tissues), ii) ex vivo 
methods (isolated animal tissues and organs) and iii) in 
silico methods: computer simulations and mathematical 
models, QSAR’s etc. Depending on the objective of the 
study, correctly selected in vitro methods in combination 
with a deep knowledge of the tested compounds (obtained 
from databases or computer simulations/QSARs, analyti-
cal chemistry, etc.) may be more appropriate for certain 
areas of interest than their animal counterparts. 110
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Table 1. Overview of validated/accepted methods (adopted with minor modifications and updates from the AltTox web-site, www.alttox.org).
End-point and 
Method Name
Test 
Type1
Endorsement of Sci-
entific Validity Regulatory Acceptance
Lead 
Authority
Subsequent 
Endorse-
ment
National/ Regional
(for methods not yet accepted inter-
nationally)
International
acceptance
Acute aquatic toxicity
Upper threshold concentration step-
down approach In vivo ESAC (2006)
Acute mammalian toxicity (oral)
  Acute toxic class method In vivo   ESAC 
(2007) OECD TG 423 (2001)
  Fixed dose procedure In vivo   ESAC 
(2007) OECD TG 420 (2001)
 U p - a n d - d o w n  p r o c e d u r e In vivo ICCVAM (2001) ESAC 
(2007) OECD TG 425 (2006)
  Normal human keratinocyte neutral 
red uptake (NHK NRU) assay In vitro2 ICCVAM (2006)   US agencies (2008) Draft OECD TG
    Balb/c 3T3 neutral red uptake assay In vitro2 ICCVAM (2006)   US agencies (2008) Draft OECD TG
Acute mammalian toxicity (inhalation)
Acute toxic class method In vivo     OECD TG 436
  Fixed concentration 
procedure In vivo     Draft TG OECD 433
Chronic toxicity
Ending 1-year dog studies of pesti-
cides In vivo ESAC 
(2006)   Revised US EPA Pesticide Data Requirements
Dermal penetration
In vitro skin absorption methods  In vitro
ex-vivo
OECD Expert 
Group (2002)   OECD TG 428 (2004)
Endocrine mechanistic screens
Androgen receptor binding assay 
(rat prostate) In vitro     OPPTS TG 890.1150 (EPA, 2009)
  Aromatase inhibition assay 
(human recombinant) In vitro     OPPTS TG 890.1200 (EPA, 2009)
  ER-alpha transcriptional activation 
assay for estrogen agnoists3 In vitro     OECD TG 455 (2009)
  Estrogen receptor binding assay In vitro     OPPTS TG 890.1250 (EPA, 2009)
  Steroidogenesis 
(H295R human cell line) In vitro     OPPTS TG 890.1550 (EPA, 2009) Draft OECD TG
  US EPA Tier 1 
Screening Battery
In vitro/
In vivo     US EPA (2009)
Eye corrosion
Bovine corneal opacity permeability 
(BCOP) test Ex-vivo ICCVAM (2007) ESAC (2007)
JaCVAM (2009)
OECD TG 437 (2009)
  Isolated chicken eye (ICE) test Ex-vivo ICCVAM (2007) ESAC (2007)
JaCVAM (2009) OECD TG 438 (2009)
  Hen’s egg test-chorioallantoic mem-
brane (HET-CAM)
In vitro/ 
Ex-vivo    EU Competent Authorities for Dangerous 
Substances Directive
  Isolated rabbit eye test Ex-vivo    EU Competent Authorities for Dangerous 
Substances Directive
Eye irritation
Cytosensor Microphysiometer modi-
fied (cytotoxicity/cell-function based 
in vitro assay)
In vitro ESAC (2009)      
  Cytotoxicity/cell-function based in 
vitro assay: Fluorescein Leakage In vitro ESAC (2009)      
table continued on the next page111
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End-point and 
Method Name
Test 
Type1
Endorsement of Sci-
entific Validity Regulatory Acceptance
Lead 
Authority
Subsequent 
Endorse-
ment
National/ Regional
(for methods not yet accepted inter-
nationally)
International
acceptance
Genotoxicity
Bacterial reverse mutation (Ames) test In vitro     OECD TG 471 (1997)
  In vitro cell gene mutation test In vitro     OECD TG 476 (1997)
  In vitro chromosomal aberration test In vitro     OECD TG 473 (1997)
  In vitro micronucleus test In vitro ESAC (2006)   Draft OECD TG 487
  In vitro sister chromatid exchange test In vitro     OECD TG 479 (1986)
  In vitro unscheduled DNA synthesis 
test In vitro     OECD TG 482 (1986)
  Saccharomyces cerevisiae gene muta-
tion assay In vitro     OECD TG 480 (1986)
  Saacharomyces cerevisiae mitotic 
recombination assay In vitro     OECD TG 481 (1986)
Hematotoxicity: acute neutropenia
Colony forming unit granulocyte mac-
rophage (CFU-GM) assay In vitro ESAC (2006)      
Phototoxicity
3T3 Neutral Red Uptake Phototoxic-
ity Test In vitro ESAC (1997)   OECD TG 432 (2004)
  3T3 NRU Phototoxicity Test: Applica-
tion to UV filter chemicals In vitro ESAC (1998)   OECD TG 432 (2004)
Pyrogenicity
Human whole blood IL-1 In vitro ESAC (2006) ICCVAM (2008)4 European Pharmacopeia; US agencies
  Human whole blood IL-6 In vitro ESAC (2006) ICCVAM (2008)4 European Pharmacopeia; US agencies
  Human cryopreserved whole blood 
IL-1 In vitro ESAC (2006) ICCVAM (2008)4 European Pharmacopeia; US agencies
 P B M C  I L - 6 In vitro ESAC (2006) ICCVAM (2008)4 European Pharmacopeia; US agencies
 M M 6  I L - 6 In vitro ESAC (2006) ICCVAM (2008)4 European Pharmacopeia; US agencies
  Limulus amebocyte lysate (LAL) test In vitro    EDQM/European Pharmacopeia;
US Pharmacopeia 
Reproductive & developmental toxicity
Embryonic stem cell test In vitro ESAC (2002)      
 M i c r o m a s s  a s s a y Ex vivo ESAC (2002)      
  Whole rat embryo assay Ex vivo ESAC (2002)      
Skin corrosion
Rat skin transcutaneous electrical resis-
tance (TER)assay Ex vivo ESAC (1998) ICCVAM (2002) OECD TG 430 (2004)
  Corrositex® noncellular membrane In vitro ICCVAM (1999) ESAC (2000) OECD TG 435 (2006)
  EpiSkin® human skin model In vitro ESAC (1998) ICCVAM (2002) OECD TG 431 (2004)
 E p i D e r m TM human skin model In vitro ESAC (1998) ICCVAM (2002) OECD TG 431 (2004)
  EST-1000 human reconstructed epi-
dermis In vitro ESAC (2009)   OECD TG 431 (2004)
 S k i n E t h i c TM human skin model In vitro ESAC (2006)   OECD TG 431 (2004)
Skin irritation
EpiSkin® skin irritation test In vitro ESAC (2007)   EU test method B.46 in COM 
regulation 440/2008/EC OECD TG 439 (2010)
 E p i D e r m TM skin irritation test In vitro ESAC (2007)5   EU test method B.46 in COM 
regulation 440/2008/EC
 E p i D e r m TM Modified SIT In vitro ESAC (2008)   EU test method B.46 in COM 
regulation 440/2008/EC OECD TG 439 (2010)
  SkinEthic RHE model In vitro ESAC (2008)   EU test method B.46 in COM 
regulation 440/2008/EC OECD TG 439 (2010)
table continued on the next page
Table 1. Continued112
Helena Kandárová, Silvia Letašiová
Alternative methods in toxicology
ISSN: 1337-6853 (print version) | 1337-9569 (electronic version)
Advantages of in vitro tests: 
•  controlled testing conditions,
•  high level of standardisation,
•  reduction of variability between experiments,
•  lack of systemic effects,
•  testing is fast and in most instances inexpensive,
•  small amount of test material is required,
•  limited amount of toxic waste is produced,
•  human cells and tissues can be used,
•  transgenic cells carrying human genes can be used,
•  reduction of testing in animals.
Limitations of most in vitro tests:
•  interactions between tissues and organs cannot be 
tested, 
• with  most  in vitro test systems, in vivo dose-
responses cannot be obtained for human risk 
assessment,
•  systemic effects cannot be evaluated,
•  pharmacokinetics cannot be evaluated,
•  chronic effects cannot yet be tested,
•  technical limitations: solubility, reaction with 
plastics, lack of in vivo-like barrier properties. 
Overview of alternative methods validated 
and endorsed by ECVAM, ICCVAM, OECD 
or other regulatory organisations
Once a method has been scientifically validated, it can 
enter the process of regulatory acceptance and guideline 
adoption. Regulatory acceptance procedures vary among 
countries as well as among regulatory agencies within 
the same country. Therefore, the Organization for 
Economic Cooperation and Development (OECD) 
promotes the harmonization of international regulatory 
acceptance providing the Guidance Document (GD) on 
the Validation and International Acceptance of New or 
Updated Test Methods for Hazard Assessment (OECD, 
2005). Adherence to the principles defined in the OECD 
GD 34 increases the likelihood of the adoption of the 
a new or modified method. 
Table 1 is adopted with minor modification from the 
AltTox web-site, (www.alttox.org) and provides an over-
view of the alternative toxicity test methods that are con-
sidered valid according to accepted international criteria. 
The test methods listed in this table have been judged to 
be scientifically valid by ECVAM, ICCVAM, JaCVAM and 
the OECD. Although uncommon, a test method may also 
be accepted for regulatory use without formal validation. 
Conclusion
A number of validated and pre-validated methods exist 
that can be used as partial or full replacements of animal 
experiments (e.g. genotoxicity, testing for local toxicity 
effects as skin corrosion, irritation, quality control of 
biologicals, production of monoclonal antibodies, safety 
testing of final cosmetic products).
As proven by several international validation studies, 
alternative methods have potential to reduce the number 
End-point and 
Method Name
Test 
Type1
Endorsement of Sci-
entific Validity Regulatory Acceptance
Lead 
Authority
Subsequent 
Endorse-
ment
National/ Regional
(for methods not yet accepted inter-
nationally)
International
acceptance
Skin sensitization
  Reduced LLNA In vivo ESAC (2007) ICCVAM (2009)  
  Local lymph node assay (LLNA) In vivo ICCVAM (1999) ESAC (1999) OECD TG 429 
(2002), (2010)
Nonradiolabelled LLNA: DA In vivo ICCVAM 
(2009)6 JaCVAM (2008) OECD TG 
422A (2010)
LLNA: BrdU-ELISA In vivo ICCVAM 
(2009)6   OECD TG 422B 
(2010)
Vaccine potency
  ELISA for erysipelas vaccines batch 
potency testing In vitro ESAC (2002)   EDQM/European Pharmacopeia
  ELISA for human tetanus vaccines 
batch potency testing In vitro ESAC (2000)   EDQM/European Pharmacopeia
Toxin binding inhibition test for human 
tetanus vaccines batch potency testing In vitro ESAC (2000)   EDQM/European Pharmacopeia
1 All in vitro and ex vivo methods listed; in vivo methods proposed to reduce or refine animal use also listed
2 Replaces animal use for initial dose setting, but in vivo test required to complete assessment
3 TA assay is in process of being formally validated, but included here because of OECD TG
4 Subject to product-specific validation to demonstrate equivalence to the rabbit pyrogen test (RPT)
5 Only positive test results accepted in the 2007 endorsement
6 ICCVAM recommendations being finalized
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of test animals needed for experiments or even replace 
the whole animal test. Testing strategies combining in 
vitro, ex vivo and in silico methods could be successful 
for areas where a single alternative method may currently 
be failing. 
When developing alternative methods for more 
c o m p l e x  t o x i c i t y  e n d p o i n t s ,  i t  w i l l  b e  n e c e s s a r y  t o  
investigate the toxicology pathways and mechanisms of 
toxic action. At the same time, we will need to reconsider 
the predictive ability of the traditional animal tests and 
their concordance with effects observed in man. These 
considerations will greatly enhance our ability to produce 
relevant and reliable alternative methods for prediction of 
human health effects.
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